Hyperkalaemia: Again

Nephrology Dialysis Transplantation

Volumn 19, Issue 9, 2004, Pages 2163-2166

  Gross, Peter ^a   Pistrosch, Frank ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Aldosterone antagonists; Hyperkalaemia; Hyporeninaemic hypoaldosteronism

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; COTRIMOXAZOLE; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FLUDROCORTISONE; FUROSEMIDE; GLUCONATE CALCIUM; HEPARIN; HEPARINOID; INDOMETACIN; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAMIDINE; PLACEBO; POTASSIUM; SALBUTAMOL; SOMATOSTATIN; SPIRONOLACTONE; TACROLIMUS; UREA;

ARTERIOSCLEROSIS; BLOOD ANALYSIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEATH; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG INDICATION; DRUG WITHDRAWAL; EDITORIAL; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOALDOSTERONISM; KIDNEY FAILURE; MORBIDITY; MORTALITY; OBESITY; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; QUADRIPLEGIA; RESUSCITATION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; UREMIA;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG INTERACTIONS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERKALEMIA; RISK FACTORS;

EID: 4544247299     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh284     Document Type: Editorial

References (13)

1. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717
2. Pitt B, Remme WJ, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321
3. Fuster D, Frey FJ, Ferrari P. Bedrohliche Hyperkaliämie als Folge der neuen Behandlungsstrategien der Herzinsuffizienz. Praxis 2000; 89: 2073-2076
4. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone. Am J Med 2001; 110: 438-441
5. Hu Y, Carpenter JP, Cheung AT. Life-threatening hyperkalemia: a complication of spironolactone for heart-failure in a patient with renal insufficiency. Anest Analg 2002; 95: 35-41
6. The RALES investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. Am J Cardiol 1996; 78: 902-907
7. Tan SY, Shapiro R, Franco R et al. Indomethacin-induced prostaglandin inhibition with hyperkalemia. Ann Intern Med 1979; 90: 783-785
8. Patel P, Mandal B. Hyperkalemic quadriparesis secondary to chronic diclofenac treatment. Postgrad Med J 2001; 77: 55-51
9. Hay E, Derazon H, Bukish N et al. Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE-inhibitor and potassium rich diet. J Emerg Med 2002; 22: 348-352
10. Caliskan Y, Kalayoglu-Besisik S, Sargin D et al. Cyclosporin-associated hyperkalemia: report of four allogeneic blood stem-cell transplant cases. Transplantation 2003; 75: 1069-1071
11. Oeshi M, Yagi T, Uroshihara N et al. A case of hyperkalemic distal renal tubular acidosis secondary to tacrolimus in living donor liver transplantation. Transplant Proc 2000; 32: 2225-2226
12. Kamel KS, Ethier JH, Quaggin S et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. J Am Soc Nephrol 1992; 2: 1279-1284
13. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68